Read our catalogue for safety testing of CHO Cell Banks
To Continue Building Analytical Capabilities for Testing Drugs and Vaccines Glasgow, UK – April 27, 2016: Sartorius Stedim BioOutsource, a leading provider of contract testing services to the biopharmaceutical industry, is pleased to announce that it is looking to almost double the scientific workforce at its Glasgow facilities in 2016. The new staff will help More
How Providing Comprehensive Data Can Accelerate Drug Development Glasgow, UK – April 21, 2016: Sartorius Stedim BioOutsource today announced that its scientific experts will be presenting a live webinar about optimizing biosimilar analysis on Thursday, June 2, at 3 pm BST, 10 am EDT. The webinar is essential listening for researchers who want to understand More
Sartorius Stedim BioOutsource Introduces Assays for Testing Biosimilarity of Three Leading Biologics
New ready-to-use assays enable quick and simple generation of precise biosimilar comparability data Glasgow, UK – March 22, 2016: Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, presents a range of ready-to-use assays for testing Actemra, Stelara and Lucentis biosimilars. The new assays, launched by SSB’s subsidiary Sartorius Stedim BioOutsource, will More
Our Chief Scientific Officer, Daniel Galbraith recently spoke to Biocompare about ‘Smarter Bioprocess Design for Smoother Upscale’. To read the full article, click here.
Demonstrating fingerprint-like similarity View webinar here.
Sartorius Stedim BioOutsource Contract Testing Facility in Glasgow Successfully Passes FDA Inspection
Certified quality of analytical services for developers of biologics and biosimilars Goettingen, GER | Glasgow, UK – March 2, 2016: Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, is pleased to announce that the Glasgow facility of its subsidiary Sartorius Stedim BioOutsource Ltd. has successfully passed an inspection by the U.S. More
Our Director of R&D and Technical Services, Dr. Catriona Thomson recently spoke to ‘Pharmaceutical Technology’ about the challenges of developing and validating an ADCC methodology, including the difference between the classical ADCC assay and the reporter bioassay. To read the full article please click here.
Rapidly reveals the factors to consider when using ADCC assays for producing precise biosimilar comparability data Glasgow, UK – November 17, 2015: Sartorius Stedim Biotech (SSB) BioOutsource today announced a new video is now available on-line explaining how to overcome the issues associated with using antibody-dependent cell-mediated cytotoxicity (ADCC) assays. The bite-sized video outlines the More
Offering scientists an opportunity for face-to-face meetings to discuss strategies for accelerating biosimilar development Glasgow, UK – November 12, 2015: Sartorius Stedim Biotech (SSB) BioOutsource today announced its expert technical staff will be speaking at and/or attending BIOLATAM, Biosimilars LATAM and Biosimilars and Biobetters conferences from November 16-19. This will provide developers of biosimilars with More